ChroMedX Announces Completion of HemoPalm Prototype Cartridge

Logo

Toronto, ON -- (SBWire) -- 09/08/2015 --ChroMedX Corp. (the "Company") (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report the completion of the HemoPalmTM System Prototype Cartridge.

In conjunction with the previously announced ENGAGE grant with McMaster University's Manufacturing Research Institute (MMRI), the Company has completed the fabrication of the prototype HemoPalmTM cartridge, a key component of the HemoPalmTM analysis system. MMRI produced the prototype by micromachining and testing of cartridge operation including calibration fluid pouch activation and microfluidic flow has already begun. Development of CO-oximetry calibration algorithms at McMaster University is underway.

Management is making available a photo of the see-through HemoPalmTM prototype cartridge identifying key components. The see through material allows easy observation of fluid flow during cartridge testing. The image can be pulled off this link:

https://static1.squarespace.com/static/52cad214e4b0d4d2bd05e2a4/t/55ea026ee4b0d610b736236d/1441399408107/?format=500w

"This is the first major step in the completion of the HemoPalmTM system alpha prototype. The cartridge is a critical element of the system and contains several novel features that set it apart from competitive products. Micromachining of the prototype cartridges has allowed rapid design modifications when needed, avoiding the time and cost of modifications to conventional plastic injection molds. Needless to say, we are very pleased with our collaboration with McMaster." said Dr. Wayne Maddever, President & CEO, ChroMedX Corp.

The Company is also pleased to present a 3D schematic video of the HemoPalmTM Analyzer system which demonstrates the sequence of operations commencing with the scanning of the cartridge for identification followed by spectroscopic CO-oximetry measurement, biosensor fluid calibration and biosensor measurement of blood gases and electrolytes. The video can be viewed by clicking this link: https://www.youtube.com/watch?v=PQ38FLtRTSk

ChroMedX recently announced the engagement of Polygenesis Corporation to complete the development of the biosensor technology aspect of the HemoPalmTM system as well as complete the development of the prototype analyzer.

About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.
Facebook: http://facebook.com/ChroMedXcorp
Twitter: http://www.twitter.com/ChroMedXcorp

Media Relations Contact

Janet Vasquez
JV Public Relations NY Inc.
212-645-5498
http://www.chromedx.com

View this press release online at: http://rwire.com/623613